Howzitgoing
15 hours ago
FB post: Therapeutic Solutions International
Never say never! Listen carefully to what Franco says about the state of immunotherapy development.
Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It
Stem Cell Modification of Cancer Microenvironment Shown to Increase Ability of Immune System to Stop Breast Cancer
September 15, 2023 09:00 AM Eastern Daylight Time
ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International, Inc. (TSOI) announced today new data and a patent filing from its Subsidiary Company Res Nova Bio which, according to Company scientists, is a potential breakthrough in the field of immunotherapy of cancer.
The conventional dogma, which is supported by numerous well performed studies, is that stem cell administration helps cancer to grow. This is because cancer cells thrive on growth factors generated by stem cells.
To the surprise of Res Nova scientists, administration of multiple types of mesenchymal stem cells increased the efficacy of immunotherapies which act through activation of T cells. Based on preliminary data it is believed that administration of regenerative cells results in altering the tumor environment which makes it easier for T cells to enter the cancer.
“Given that our founding company possesses a wealth of clinical data on mesenchymal stem cells, including FDA Phase III in ARDS, we are currently seeking partners to explore this potentially game-changing discovery,” said Famela Ramos, President, and CEO of Res Nova.
“As a practicing physician I see first-hand the urgent need for out of the box approaches to cancer,” said Dr. James Veltmeyer, Chief Medical Officer. “To think that in less than a year Res Nova has leveraged technologies ranging from stem cells to the abortion pill to create preclinical and early clinical products is unparallel in my opinion.”
“We live in the Golden Age of cancer immunotherapy, and we are at the forefront. Unfortunately, some of the most effective of these therapies cannot enter solid tumors. For example, CAR-T cells have produced miraculous results in leukemias and lymphomas, but they lack efficacy in the majority of cancers,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International.
BigBadWolf
2 days ago
I'll let all do the math Authorized Shares 9,000,000,000 01/15/2025
Outstanding Shares 5,799,885,024 01/15/2025
Restricted 1,648,953,148 01/15/2025
Unrestricted 4,150,931,876 01/15/2025
Held at DTC 4,101,417,549 01/15/2025
I’ll let all do the math frown Authorized Shares 6,500,000,000 12/30/2024
Outstanding Shares 5,705,269,639 12/30/2024
Restricted 1,648,953,148 12/30/2024
Unrestricted 4,056,316,491 12/30/2024
Held at DTC 3,881,802,164 12/30/2024
Authorized Shares 6,500,000,000 11/29/2024
Outstanding Shares 5,255,269,639 11/29/2024 >132,564,103
Restricted 1,648,953,148 11/29/2024
Unrestricted 3,606,316,491 11/29/2024 >182,078,430
Held at DTC 3,556,802,164 11/29/2024 >132,564,103
Authorized Shares 6,500,000,000 11/19/2024
Outstanding Shares 5,122,705,536 11/19/2024
Restricted 1,648,953,148 11/19/2024
Unrestricted 3,473,752,388 11/19/2024
Held at DTC 3,424,238,061 11/19/2024
As of November 20, 2024, 5,122,705,536 shares of the registrant’s common stock, par value of $0.001 per shares, were outstanding
Updated SS Authorized Shares 6,500,000,000 11/04/2024
Outstanding Shares 5,122,705,536 11/04/2024
Restricted 1,649,049,648M11/04/2024 >96,500
Unrestricted 3,473,655,888 11/04/2024
Held at DTC 3,424,238,061 11/04/2024 <96,500
Authorized Shares 6,500,000,000 10/03/2024
Outstanding Shares 5,122,705,536n10/03/2024
Restrictedn1,648,953,148 10/03/2024
Unrestricted 3,473,752,388 10/03/2024
Held at DTC 3,424,334,561 10/03/2024
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175130129&txt2find=Share
Authorized Shares 6,500,000,000 08/20/2024
Outstanding Shares 5,057,149,981 08/20/2024 >173,054,706
Restricted 1,603,397,593 08/20/2024
Unrestricted 3,453,752,388 08/20/2024
Held at DTC 3,231,279,855 08/20/2024
As of August 19, 2024, 4,884,095,275 shares of the registrant’s common stock, par value of $0.001 per shares, were outstanding.
…always loved possible coincidences of wonder why’s & mathematics
https://www.otcmarkets.com/filing/html?id=17873088&guid=pLL-keKdSJI-B3h
https://www.otcmarkets.com/filing/html?id=17873091&guid=pLL-keKdSJI-B3h
BigBadWolf
2 days ago
Buy/Sell Ratio Buy: 1,088,653 Neutral: 2,519,825 Sell: 189,230,770
Time Price Size Type B/S Bid Price Ask Price Buy Ind. Total Volume Num Exch.
15:15:56 0.00019 94,615,385 avg. Sell 0.0002 0.0003 192,839,248 10 nasd
15:14:55 0.0002 47,515,736 Sell 0.0002 0.0003 98,223,863 9 nasd
15:14:52 0.0002 37,441,393 Sell 0.0002 0.0003 50,708,127 8 nasd
15:14:52 0.0002 9,658,256 Sell 0.0002 0.0003 13,266,734 7 nasd
14:42:00 0.00025 325 0.0002 0.0003 3,608,478 6 nasd
12:35:12 0.00025 2,500,000 0.0002 0.0003 3,608,153 5 nasd
11:50:35 0.00025 19,500 0.0002 0.0003 1,108,153 4 nasd
10:35:22 0.0003 38,653 Buy 0.0002 0.0003 1,088,653 3 nasd
10:35:15 0.0003 50,000 Buy 0.0002 0.0003 1,050,000 2 nasd
10:32:44 0.0003 1,000,000 Buy 0.0002 0.0003 1,000,000 1 nasd